by John Conrad | Jun 7, 2024 | NewsBrief
AbbVie’s strategic acquisition of ImmunoGen for $10.1 billion in November 2023 is already showing promising results. The deal, which included the antibody-drug conjugate (ADC) Elahere, has yielded positive outcomes in a recent Phase 2 study. According to...
